ArticleTheranostics2022
The peroxisome proliferator-activated receptor agonist rosiglitazone specifically represses tumour metastatic potential in chromatin inaccessibility-mediated FABP4-deficient gastric cancer.
Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Lipid-Soluble Signaling Molecular Model Predicts Prognosis and Immunotherapy Response in Gastric Cancer.Lipids · 2026Article
- Doxorubicin enhances adipogenesis in an FGF2-dependent manner and induces a tumour-promoting secretory phenotype.Journal of bone oncology · 2026Article
- Repurposing Rosiglitazone Induces Apoptosis Accompanied by Impaired Antioxidant Defense in Cholangiocarcinoma Cells: Findings from Proteomic and Functional Analyses.Pharmaceuticals (Basel, Switzerland) · 2025Article
- FABP4 in lipid metabolism and the tumor microenvironment: mechanisms and therapeutic potential.Lipids in health and disease · 2025Review
- Systematically Revealing Quantitative Multi-Target Integrative Effects of Plants With Artificial Intelligence Method.Plant biotechnology journal · 2025Article
- Fatty Acid-binding Protein 4 Exacerbates Blood-brain Barrier Disruption Through the JNK/c-Jun/MMP12 Pathway After Traumatic Brain Injury.Molecular neurobiology · 2025Article
- Cuproptosis-Related Ferroptosis Gene Signature: A Prognostic Tool for Colon Cancer Patients.Cancer reports (Hoboken, N.J.) · 2025Article
- Review
- Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with aOncology letters · 2025Article
- Multiomic analysis of familial adenomatous polyposis reveals molecular pathways associated with early tumorigenesis.Nature cancer · 2024Article
- Altered lipid metabolism promoting cardiac fibrosis is mediated by CD34Experimental & molecular medicine · 2024Article
- Adipocytes impact on gastric cancer progression: Prognostic insights and molecular features.World journal of gastrointestinal oncology · 2024Article
- ACSM5 inhibits ligamentum flavum hypertrophy by regulating lipid accumulation mediated by FABP4/PPAR signaling pathway.Biology direct · 2023Article
- Delineation of fatty acid metabolism in gastric cancer: Therapeutic implications.World journal of clinical cases · 2023Article
- Peroxisome proliferator-activated receptors regulate the progression and treatment of gastrointestinal cancers.Frontiers in pharmacology · 2023Review
- Protective effect of rosiglitazone on microscopic and oxidative stress parameters of ram sperm after freeze-thawing.Scientific reports · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.